THE PEROXISOME proliferator-activated receptor (PPAR) ligandinducible nuclear hormone receptor subfamily consists of three members, PPAR␣, PPAR␤/␦, and PPAR␥. The conformational change induced upon interaction of PPARs with their ligands activates the heterodimeric complexes that they form with retinoid-X receptors (8, 12, 16) . These activated PPAR-retinoid-X receptor complexes are then able to bind to peroxisome proliferator response elements to activate gene transcription (6, 31) . Classically, each of the three PPAR isotypes has been identified in species ranging from Xenopus to humans and are expressed in distinct tissue-specific patterns. PPAR␣ (NR1C1) is involved in fatty acid catabolism and amino acid metabolism and is primarily responsible for body energy homeostasis. PPAR␣ is highly expressed in liver, heart, skeletal muscle, intestinal mucosa, and brown adipose tissue and is metabolically very active (14) . PPAR␥ (NR1C3), highly expressed in white and brown adipose tissue, colon, and spleen, is mainly involved in adipocyte differentiation and lipid storage in adipose tissue and also in enhancing body insulin sensitivity (36) . In contrast to PPAR␣ and PPAR␥, which are highly expressed in a few tissues, PPAR␤/␦ (NR1C2) is expressed ubiquitously, but with varying levels in different tissues (3, 40) . PPAR␤/␦ has been shown to be involved in lipid metabolism, energy homeostasis, and wound healing (41) . PPAR␣, ␤/␦, and ␥ also play important roles in epidermal maturation and tissue repair processes (28) . Whether PPAR␤/␦ is pro-or anticarcinogenic is still debated: both effects have been reported in various tumor types, which might reflect different genetic defects within the tumor (27, 33) . In addition, PPAR␤/␦ has been implicated in increasing the ␤-oxidation of fatty acids in skeletal muscle and adipose tissue (9) . Furthermore, PPAR␤/␦ plays a pivotal role in regulating hepatic gene expression, which modulates glucose homeostasis in liver (17) .
Overexpression of PPAR␤/␦ has been shown to influence muscle metabolism. Previous studies have established that the mRNA expression of PPAR␦ is higher in oxidative soleus (Sol) muscle compared with the predominantly glycolytic extensor digitorum longus (EDL) muscle (19) . It was further noted that oxidative muscles also display the highest levels of PPAR-␤/␦ protein. PPAR␤/␦ overexpression promotes hyperplasia of skeletal muscle, specifically resulting in an increase in oxidative muscle fibers and capillary density. In agreement with this, overexpression of a constitutively active PPAR␤/␦ in mouse skeletal muscle was found to induce differentiation of mitochondria-rich, oxidative type I muscle fibers (42) . In addition, muscle-specific overexpression of PPAR␤/␦ has been shown to promote myonuclear density (13) . PPAR␤/␦ also plays an important role in the adaptation of skeletal muscle to environmental changes, such as long-term fasting, by increasing the number of oxidative fibers (10) . In line with these observations, muscle-specific ablation of PPAR␤/␦ causes a functional switch of the skeletal muscle fiber type toward lower oxidative capacity, which is followed by the appearance of age-dependent obesity and type 2 diabetes (38) .
Furthermore, PPAR␤/␦ ligands may upregulate fatty acid transport and oxidation, thereby reducing fatty acid-induced inflammation and insulin resistance in skeletal muscle (5, 20) . A recent report suggests that activation of PPAR␤/␦, through addition of specific agonist, enhances myogenesis in C2C12 myoblasts by increasing both myoblast proliferation and differentiation (2) . Consistent with this, loss of PPAR␤/␦ resulted in reduced proliferation of primary myoblasts and defective differentiation. In addition, a recent study reported that skeletal muscle-specific knock out of PPAR␦ in mice [PPAR␦-conditional knockout (cKO)] leads to reduced satellite cell (SC) number and impaired skeletal muscle regeneration upon cardiotoxin-mediated injury (1) . Recent results have revealed that PPAR␤/␦ positively regulates postnatal myogenesis through transcriptional activation of Gasp-1, leading to reduced activity of its downstream target myostatin (2) .
Here, using a germ line deleted PPAR␤/␦ knockout mouse model (PPAR␤/␦-null), we have further characterized the role of PPAR␤/␦ in postnatal skeletal muscle growth and regeneration. Given the increased myostatin activity in PPAR␤/␦-null muscle (2), we hypothesize that postnatal myogenesis is impaired in PPAR␤/␦-null mice. Consistent with this, PPAR␤/␦-null mice showed impaired muscle regeneration, evidenced by reduced muscle weight and decline in regenerated myofiber size and reduced centrally located myonuclei number, 28 days post-notexin administration. We also observed increased inflammatory response with reduced myoblast proliferation during later phase of regeneration in PPAR␤/␦-null regenerating tibialis anterior (TA) muscle. On the other hand, antagonism of myostatin in PPAR␤/␦-null mice resulted in increased body and muscle weight and significant hypertrophy of muscle fibers. Subsequent blockade of myostatin using the myostatin inhibitor soluble activin receptor IIB (sActRIIB) improved skeletal muscle regeneration by increasing the number of centrally formed nuclei and promoting hypertrophy of regenerated muscle fibers. Therefore, we conclude that PPAR␤/␦ positively regulates postnatal skeletal muscle myogenesis through reducing myostatin activity in mice.
MATERIALS AND METHODS
Animals. PPAR␤/␦-null mice were gifted from Professor Walter Wahli (University of Lausanne, Lausanne, Switzerland). Animals were housed and maintained at a constant temperature (20°C) with a 12:12-h light-dark cycle with ad libitum access to water at the Nanyang Technological University animal facility. Wild-type (WT) mice (C57BL/6) were purchased from the Center for Animal Resources, National University of Singapore, Singapore. All animal procedures were reviewed and approved by the Institute Animal Ethics Committee, Singapore.
Muscle injury model. Six-week-old male WT and PPAR␤/␦-null mice were anesthetized by intraperitoneal injection of a mixture of 10 mg/ml ketamine and 1 mg/ml xylazine at 0.1 ml/10 g body wt.
Fifteen microliters of notexin (10 g/ml in 0.9% saline; Latoxan, Rosans, France) were injected into the TA muscle of the left leg using a 28-gauge syringe (Hamilton, Whittier, CA). The TA muscle from the contralateral limb was used as the uninjured control. TA muscles were harvested on days 3, 5, 7 , and 28 after notexin-induced injury. For the sActRIIB myostatin antagonist trial, mice were anesthetized with ketamine and xylazine, as stated above. Fifteen microliters of notexin (10 g/ml) were injected into the TA muscle of the left leg with a 28-gauge syringe, and the contralateral limb was used as an uninjured control. The mice were injected intraperitoneally with sActRIIB (43) (4 g/g body wt) three times per week for a period of 4 wk. TA muscles were harvested on day 28 after notexin-induced injury for further histological and molecular analysis.
Histological assessment of muscle regeneration. Muscle tissues were embedded in optimal cutting temperature (Tissue-Tek, Sakura Fine TEK, Torrance, CA) compound and then frozen in liquid nitrogen cooled isopentane. Serial cross sections (10 m) were cut from the midbelly of the muscle and mounted on cryoslides for histological, immunochemical, and metabolic staining. Hematoxylin and eosin (H&E) and Van Gieson's staining were performed according to the manufacturer's instructions [catalog no. 115973-1 (solution A), 115973-2 (solution B) Merck Millipore, Singapore]. For H&E staining, the cryosections were stained with hematoxylin for 1 min and rinsed with tap water. Following 2 ϫ 1 min washes in Scott's tap water, the sections were stained with eosin for 2 min and rinsed three times in 50% ethanol and then in 70% ethanol. Sections were further rinsed for 2 min in 95% ethanol, washed 2 ϫ 2 min each in 100% ethanol, followed by 2 ϫ 5 min in xylene. The stained sections were mounted with DPX mounting reagent and allowed to dry overnight. Images were captured using the Leica CTR 6500 microscope equipped with the Leica DFC 310 FX camera (Leica, Singapore). ImagePro Plus software (Media Cybernetics, Bethesda, MD) and ImageJ software (National Institutes of Health) were used for image analysis. H&E stained images were used for cross-sectional area (CSA) measurement, and fibrotic tissue was assessed through Van Gieson's stain. The area of interstitial fibrosis was quantitatively assessed using Van Gieson's stained images and was measured according to Luz et al. (21) . Five images (magnification, ϫ10) around the lesion area from each sample were used for quantification, according to Ge et al. (11) , and calculated as the ratio of fibrotic area to CSA (%) of the images. For the contralateral uninjured control, the CSA from 1,000 myofibers from randomly selected fields were counted. For regenerated myofibers, the CSA of centrally nucleated myofibers within the field were measured.
Immunohistochemical staining for Mac-1. Frozen muscle sections (10 m) were stained for macrophages according to the previously established protocol (11) . Briefly, sections were fixed in 2% paraformaldehyde for 5 min and then permeabilized with 0.3% Triton X-100 in PBS for 5-10 min. The sections were then blocked with 10% normal goat serum (NGS) in Tris-buffered saline (TBS) for 1 h at room temperature and then incubated with primary rat anti-mouse Mac-1 antibody (1:100; BD Pharmingen, San Diego, CA) in TBS overnight at 4°C. Following incubation with goat anti-rat IgG biotinylated (1:400) secondary antibody, in 5% NGS in TBS for 1 h at room temperature, the sections were then incubated with streptavidin conjugated Alexa Fluor 488 (1:400; Invitrogen) tertiary antibody in 5% NGS in TBS for 30 min. Nuclei were counterstained with 4=6-diamidino-2-phenylindole (DAPI) (1:1,000; Invitrogen Molecular Probes, Singapore) and mounted with ProLong Gold Antifade mounting reagent (Invitrogen). Mac-1-positive cells were counted and expressed as a percentage of DAPI-positive nuclei.
Immunohistochemical staining for Pax7 and MyoD. TA muscle sections (10 m) were fixed in 4% paraformaldehyde for 5 min and then permeabilized with 0.2% PBS-Tween 20. The sections were then blocked with a solution containing 6% mouse IgG blocking reagent (MOM Immunodetection kit; Vector Laboratories) and 3% bovine serum albumin (BSA) in PBS for 1 h, followed by blocking again with MOM protein diluent with 1.5% BSA in PBS, as per the manufacturer's instruction. Muscle sections were then incubated with either mouse monoclonal anti-Pax7 (1:1,000; Developmental Studies Hybridoma Bank; DSHB, Iowa City, IA) or anti-MyoD (1:25; BD Pharmingen, San Diego, CA) primary antibody in 1.5% BSA in PBS overnight at 4°C. Following incubation with biotinylated horse antimouse IgG (1:500; Vector Laboratories), rabbit polyclonal antilaminin (1:1,000; Sigma-Aldrich, Singapore), and rabbit polyclonal anti-MyoD (1:40; Santa Cruz) antibodies for 3 h, the sections were then washed and incubated with streptavidin conjugated Alexa Fluor 488 (1:1,000; Invitrogen) and goat anti-rabbit Alexa Fluor 594 (1: 1,000; Invitrogen) for 30 min. Nuclei were counterstained with DAPI (1:5,000; Invitrogen Molecular Probes) and mounted with ProLong Gold Antifade mounting medium (Invitrogen). Pax7 ϩ /MyoD Ϫ cells were quantified in the stained sections and expressed as number of Pax7 ϩ /MyoD Ϫ cells per 100 myofiber. Succinate dehydrogenase staining. Succinate dehydrogenase (SDH) activity used to determine the overall oxidative capacity of skeletal muscles was measured using a colorimetric assay, as described by Masuda et al. (22) . Muscle sections were air-dried for 30 min and incubated in prewarmed PBS buffer containing 50 mM sodium succinate and 0.6 mM nitro blue tetrazolium (Sigma-Aldrich, Singapore) for 25 min at 37°C. The reaction was terminated by rinsing the sections thoroughly with distilled water. After dehydration and clearance by xylene, the sections were mounted using DPX (SigmaAldrich, Singapore). Images were captured using the Leica CTR 6500 microscope, equipped with the Leica DFC 310 FX camera and ImagePro Plus software (Media Cybernetics, Bethesda, MD). SDH activity was quantified using ImageJ software (National Institutes of Health) by converting the image to gray scale and measuring the gray intensity of the muscle section. The mean of the three sections was used to determine SDH activity.
Statistical analysis. Statistical differences between groups was determined using unpaired two-tailed Student's t-test, and the results were considered significant at P Ͻ 0.05 (*), P Ͻ 0.01 (**), or P Ͻ 0.001 (***). Data are expressed as means Ϯ SE.
RESULTS
PPAR␤/␦-null mice exhibit pronounced skeletal muscle atrophy. We observed reduced body weight and a significant decrease in TA, m. gastrocnemius, EDL, and Sol muscle weights in PPAR␤/␦-null mice, compared with WT ( Fig. 1 , A-C). Although no significant difference in m. quadriceps muscle weights was noted, there was a trend toward reduced muscle weight in PPAR␤/␦-null mice (Fig. 1B) . Consistent with the reduced muscle weights, a significant reduction in TA muscle fiber CSA was observed in PPAR␤/␦-null mice, compared with WT mice (Fig. 1D) , although no significant differ- ence was noted in myofiber number (data not shown). SCs play crucial roles in postnatal muscle growth and maintenance (32) . As such, we next quantified the number of Pax7 ϩ /MyoD Ϫ SCs in muscle fiber sections through immunohistochemical analysis. Results revealed a significant reduction in the number of Pax7 ϩ /MyoD Ϫ SCs in resting muscle fibers of PPAR␤/␦-null mice, compared with WT controls (Fig. 1E) .
Histological analysis of skeletal muscle during early regeneration. To further study the effect of loss of PPAR␤/␦ on postnatal myogenesis, skeletal muscle regeneration was assessed in WT and PPAR␤/␦-null mice injected with notexin. The uninjured TA muscles from both PPAR␤/␦-null and WT mice are shown in Fig. 2A , and, upon injury, both of the genotypes showed complete and extensive muscle degeneration 3 days post-notexin-induced injury ( Fig. 2A) . However, more extensive necrosis was seen on day 3 post-notexin injection in PPAR␤/␦-null mice, compared with WT mice (Fig. 2A) . At day 5 postinjury, a mixed population of hyperstained necrotic myofibers and newly developing myofibers were observed in TA muscle from both PPAR␤/␦-null mice and WT controls ( Fig. 2A) . At 7 days postinjury, nascent myofibers, characterized by centrally located nuclei and small fiber size, were abundant in TA muscle from both PPAR␤/␦-null mice and WT controls; however, visibly smaller myofibers were observed in PPAR␤/␦-null mice compared with WT controls (Fig. 2A) . Immunohistochemical analysis with Mac-1 antibodies revealed increased infiltration of macrophages in PPAR␤/ ␦-null mice at day 3 post-notexin injection (Fig. 2B) . However, no significant difference in the percentage of Mac-1-positive cells was noted between PPAR␤/␦-null mice and WT controls 28 days following notexin injection (Fig. 2C) . Collectively, these data suggest that loss of PPAR␤/␦ affects the early stages of muscle regeneration.
Reduced numbers of proliferating myoblasts in PPAR␤/␦-null regenerating muscle. We next performed MyoD immunohistochemical analysis on notexin-injured TA muscle sections to assess whether or not loss of PPAR␤/␦ affects SC activation. Results revealed a significant reduction in MyoD-positive myoblasts from 3 days post-notexin injection, with greater than 50% reduction in MyoD-positive cells noted at day 3, ϳ38% reduction at day 7, and ϳ50% reduction at day 28 postinjury in PPAR␤/␦-null TA muscle, compared with respective WT controls (Fig. 2D) . These data suggest that loss of PPAR␤/␦ significantly reduces the pool of proliferating myoblasts present in injured and regenerating skeletal muscle.
We further assessed SC self-renewal in PPAR␤/␦-null muscle through MyoD and Pax7 immunohistochemical analysis on regenerated (day 28 post-notexin injection) TA muscle sections. After injury and regeneration, we still observe a significant reduction in SC number in PPAR␤/␦-null mice compared with WT mice (Fig. 2E) . Upon further analysis, we did not find any significant difference in SC number between uninjured and regenerated TA muscle in both the genotypes (comparison not shown). These data suggest that the self-renewal capacity of SCs remains unaffected in PPAR␤/␦-null mice.
Loss of PPAR␤/␦ results in reduced centrally placed myonuclei in regenerated muscle. Histological analysis was performed to quantitatively examine muscle regeneration 28 days post-notexin-induced injury (Fig. 3A) . Morphologically, we noted an observable reduction in myofiber size in regenerated TA muscle from PPAR␤/␦-null compared with WT controls (Fig. 3A) . Subsequent analysis of myofiber CSA confirmed the reduced myofiber size in regenerated TA muscle from PPAR␤/ ␦-null mice (Fig. 3B) , which was consistent with the atrophy phenotype noted in PPAR␤/␦-null mice before injury (Fig.  1D) . Consistent with this, the weight of regenerated TA muscle was significantly lower in PPAR␤/␦-null mice compared with WT controls (Fig. 3C) . As regenerated myofibers are characterized by the presence of centrally located myonuclei (34), we next assessed the number of central myonuclei per myofiber in regenerated TA muscle from WT and PPAR␤/␦-null mice. As can be seen in Fig. 3D , loss of PPAR␤/␦ led to a significant increase in myofibers with one centrally placed nuclei, concomitant with a significant reduction in the percentage of myofibers with two and three or more centrally placed nuclei, compared with WT controls (Fig. 3D) . Specifically, the number of myofibers with one centrally placed nuclei was found to be 52.99 Ϯ 2.01% in WT and 66.76 Ϯ 1.78% in PPAR␤/␦-null mice, whereas the number of myofibers with two centrally placed nuclei were found to be 33.07 Ϯ 0.7% in WT and 26.03 Ϯ 1% in PPAR␤/␦-null, and greater than three centrally placed nuclei were found to be 13.9 Ϯ 1.53% in WT and 7.2 Ϯ 0.87% in PPAR␤/␦-null mice (P Ͻ 0.01, P Ͻ 0.001) (Fig. 3D) .
Loss of PPAR␤/␦ does not significantly alter scar tissue formation or metabolic properties of regenerated muscle.
The final phase of muscle regeneration is usually characterized by fibrotic tissue formation, which contributes to incomplete functional recovery (15) . To examine the extent of fibrotic tissue formation in regenerated TA muscle of WT and PPAR␤/␦-null mice, muscle sections were stained with Van Gieson's stain, and the extent of fibrotic tissue was quantified. Subsequent quantification of fibrotic tissue formation revealed that there was no significant difference in the area of fibrotic tissue in regenerated TA muscle sections between WT and PPAR␤/␦-null mice (Fig. 4A) .
Skeletal muscle regeneration has been shown to increase the number of oxidative muscle fibers (4). Hence, we further assessed the proportion of oxidative muscle fibers in regenerated (day 28 post-notexin injection) TA muscles through assessing SDH activity (22) . As expected, there was an increase in SDH activity, as measured through increased SDH staining, in regenerated TA muscles from both WT and PPAR␤/␦-null mice, compared with respective uninjured controls. However, it is noteworthy to mention that SDH staining, and thus activity, was comparable between uninjured TA muscle from WT and PPAR␤/␦-null mice and between regenerated TA muscle from WT and PPAR␤/␦-null mice (Fig. 4, B and C) . These results indicate that loss of PPAR␤/␦ does not lead to a change in oxidative capacity in injured skeletal muscle tissue.
Blockade of myostatin leads to skeletal muscle hypertrophy in PPAR␤/␦-null mice pre-and postinjury. Myostatin has been established to bind with high affinity to sActRIIB (18) , inhibiting myostatin signaling and contributing to increased musculature. Hence, we tested the effect of myostatin inhibition in PPAR␤/␦-null mice using sActRIIB. Increased body weight was observed in PPAR␤/␦-null mice administered sActRIIB (4 g/g body wt), compared with dialysis buffer (DB) injected control mice (Fig. 5A) . However, no significant difference in muscle weights was observed in PPAR␤/␦-null mice treated with sActRIIB, compared with control-treated mice (Fig. 5, B  and C) . We further noted an increase in muscle fiber CSA in sActRIIB injected PPAR␤/␦-null mice (Fig. 5D ) compared with control-treated mice, which is consistent with skeletal muscle hypertrophy and loss of myostatin activity. These data suggest that the reduction in body weight, muscle weights, and muscle CSA observed in PPAR␤/␦-null mice may be due to enhanced activity of myostatin.
We further tested the effect of sActRIIB injection on skeletal muscle regeneration in PPAR␤/␦-null mice. We observed no significant change in regenerated (day 28 post-notexin-induced injury) muscle weights of PPAR␤/␦-null mice treated with sActRIIB, compared with respective DB treated control (data not shown). Despite this, we did find a significant increase in muscle fiber CSA, consistent with hypertrophy, in regenerated TA muscle sections of sActRIIB treated PPAR␤/␦-null mice, compared with respective DB-treated control (Fig. 5E) . A significant increase in the number of centrally formed nuclei was also observed in regenerated TA muscle sections from PPAR␤/␦-null mice treated with sActRIIB, compared with respective DB treated control (Fig. 5F ).
Taken together, these data suggest that sActRIIB-mediated blockade of myostatin is able to improve skeletal muscle regeneration in PPAR␤/␦-null mice in response to injury.
DISCUSSION
Overexpression of constitutively active PPAR␤/␦ in mouse skeletal muscle promotes muscle development and enhances myogenesis by increasing both myoblast proliferation and differentiation in C2C12 myoblasts (2, 13, 42) . In this study, we used notexin-induced muscle injury to analyze the regeneration capacity of PPAR␤/␦-null muscle and, therefore, understand the role of PPAR␤/␦ in postnatal myogenesis.
During postnatal myogenesis PPAR␤/␦-null mice show reduced body weight, reduced TA, gastrocnemius, EDL, and Sol muscle weight (Fig. 1, A-C) . However, in contrast to the results presented here, Angione et al. (1) have shown no significant change in body weight and muscle weights in skeletal muscle-specific PPAR␤/␦ knockout mice (PPAR␦-cKO). It is quite possible that the differences noted in body and muscle weights between Angione et al. and the present study could be due to the different transgenic mouse models used. In particular, the Angione et al. study made use of muscle-specific PPAR␤/␦ knockout mice, whereas we have used germ linedeleted PPAR␤/␦-null mouse model. However, it is important to highlight that Angione et al. assessed for differences in body weight between female WT and PPAR␦-cKO mice, whereas we have assessed differences in body and muscle weights between male WT and PPAR␤/␦-null mice. Thus the variation in body weights and muscle weights observed between the study by Angione et al. and our present study could be due to sexual dimorphism, as previous reports indicate that hormones such as estrogen influence muscle growth (7, 24) . However, further research will need to be performed to ascertain whether PPAR␤/␦ influences estrogen levels and thereby affects muscle mass. We further noted decreased muscle fiber size (atrophy) in PPAR␤/␦-null mice compared with WT mice (Fig. 1D) , with no appreciable change in fiber number (data not shown). Such atrophy could be due to reduced SC number and impaired SC function. Previous work from our laboratory has also demonstrated that myostatin is a potent negative regulator of SC activation and function (25) , and excess myostatin levels have been shown to promote muscle wasting (26) . Since PPAR␤/␦-null mice have been previously shown to have increased myostatin activity (2), it is quite possible that the observed atrophy may be due to increased myostatin activity. SCs between resting muscle and regenerated muscle (day 28 post-notexin injection) in PPAR␤/␦-null mice are comparable, we suggest that SCs from PPAR␤/␦-null mice are able to self-renew their population normally during postnatal growth (Fig. 2E) . Given that SC self-renewal may not be impaired in PPAR␤/␦-null mice, we predict that the reduction in SCs is due to alterations in the specification of SCs during embryonic/fetal development (30) in PPAR␤/␦-null mice. It was previously
shown that a subset of Pax3/Pax7 expressing myoblasts in dermomyotome of embryonic days 16.5 to 18.5 mature into SCs (35) . Perhaps lack of PPAR␤/␦ is responsible for either specification of these myoblasts in the dermomyotome or for their replication. Much more extensive investigations are required to investigate the precise mechanism of PPAR␤/␦ in regulating SC specification during fetal growth. Interestingly, in Xenopus development, PPAR␤/␦ is essential for muscle and . E: frequency distribution of muscle fiber CSA (m 2 ) in regenerated (day 28 post-notexin-induced injury) TA muscle from PPAR␤/␦-null mice injected with either DB (day 28-DB) or sActRIIB (4 g/g body wt) (day 28-sActRIIB). F: quantification of centrally formed myonuclei within regenerated (day 28 post-notexin-induced injury) TA myofibers from PPAR␤/␦-null mice injected with either DB (day 28-DB) or sActRIIB (4 g/g body wt) (day 28-sActRIIB). Values are means Ϯ SE; n ϭ 3 in each group. Statistical differences are indicated in relevant panels: *P Ͻ 0.05 and **P Ͻ 0.01. neural differentiation as early as in gastrulation when PPAR␤/␦ governs a massive wave of transcriptional modifications affecting the later differentiation of muscle and brain (37) .
SCs are proven muscle stem cells that give rise to new muscle fibers during skeletal muscle regeneration (32) . Therefore, we next assessed the myogenic function of PPAR␤/␦-null SCs by studying muscle regeneration. During the early phase of muscle regeneration, we found significantly increased macrophage infiltration in PPAR␤/␦-null injured muscle after 3 days of notexin-induced injury (Fig. 2, A and B) . In agreement with the data presented here, reduced macrophage infiltration has been reported in diabetic nephropathy mice treated with PPAR␤/␦ agonist and activation of PPAR␤/␦ has been further shown to inhibit macrophage recruitment and vascular inflammatory gene expression (23, 39) . We also observed reduced numbers of MyoD-positive activated SCs at day 3 in regenerating PPAR␤/␦-null TA skeletal muscle (Fig. 2D) . Since PPAR␤/␦-null mice have reduced SCs to begin with, which have previously been shown to proliferate slower (2), we speculate that both of these factors contribute to the reduced number of MyoD-positive myoblasts observed at day 3 of regeneration. In addition, previously published results from our laboratory have revealed increased myostatin activity in PPAR␤/␦-null mice, which leads to reduced proliferation and differentiation of primary myoblasts (2). Thus it is quite possible that the reduced numbers of MyoD-positive myoblasts in PPAR␤/␦-null mice during regeneration is due to increased expression/activity of myostatin observed in these mice. It is noteworthy to mention that, despite increased macrophage infiltration and impaired SC activation in PPAR␤/␦-null mice, we observed no difference in fibrotic tissue formation in regenerated muscle (day 28 post-notexin injection) between WT and PPAR␤/␦-null mice (Fig. 4A) .
In agreement with Angione et al.
(1), we also observed a reduced differentiation potential of myoblasts as the histology on PPAR␤/␦-null regenerated skeletal muscle at day 28 confirmed a severely atrophied regenerated muscle fiber with lower number of centrally formed nuclei (Fig. 3, B and D) . Several factors have been shown to affect SC activation, proliferation, and differentiation (1, 29) . Previously, our laboratory has shown that myostatin is a potent negative regulator of SC activation and myoblast proliferation (25) . Therefore, lack of myostatin improved muscle healing by increasing both myoblast proliferation and differentiation. Since the PPAR␤/ ␦-null mice used in this study have increased myostatin activity (2), it is quite possible that the impaired SCs function and reduced myogenesis observed in these mice could be due to increased myostatin. To confirm the role of myostatin in PPAR␤/␦-null mice during regeneration, we induced muscle injury via notexin injection and blocked excess myostatin signaling via treatment with a dominant-negative soluble receptor decoy (sActRIIB) (44) . The results confirmed that blockade of excess myostatin signaling in PPAR␤/␦-null mice resulted in increased muscle hypertrophy of not only resting muscle, but also regenerated (day 28 post-notexin injection) muscle. Therefore, we propose that increased myostatin activity is at least in part responsible for the atrophy phenotype observed in PPAR␤/␦-null mice.
In summary, PPAR␤/␦ plays a critical role in muscle regeneration from early inflammatory response, primary myogenesis, and formation of completely regenerated myofibers.
Based on the results from this study, we propose that PPAR␤/␦ regulates SC number, function, and myoblast differentiation via regulation of myostatin.
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